This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top analysts changed outlook on top names. See analyst ratings page for all changes.
Stocks · News reference
Top 3 Health Care Stocks That May Keep You Up At Night In June
Health care stocks flashing warning to momentum investors. RSI indicator shows overbought for DFTX, NRIX, GALT. Check BZ Edge Rankings for more.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
B of A Securities Initiates Coverage On Definium Therapeutics with Buy Rating, Announces Price Target of $75
B of A Securities analyst Tazeen Ahmad initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Buy rating and announces Price Target of $75.
Maxim Group Maintains Buy on Definium Therapeutics, Raises Price Target to $55
Maxim Group maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $50 to $55.
Jones Trading Maintains Buy on Definium Therapeutics, Raises Price Target to $90
Jones Trading analyst Justin Walsh maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $74 to $90.
Galectin Therapeutics Q2 EPS $(0.14) Misses $(0.09) Estimate
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.09) by 55.56 percent. This is a 16.67 percent decrease over losses of $(0.12) per
8-K filing — GALECTIN THERAPEUTICS INC (GALT)
Filed: 2026-08-14 AccNo: 0001140361-26-032946 Size: 887 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits